PAREXEL Recognized with Awards for Innovation and Expertise in Real-World Evidence
The Fierce Innovation Awards: Life Sciences Edition recently selected PAREXEL’s collaboration with Datavant as “Best in Show” for Best Outsourcing Partner in the annual Fierce Innovation Report. Announced earlier this year, the alliance aims to enable sponsors to leverage the wealth of data available today and enhance drug development and commercialization processes by linking de-identified healthcare data from a variety of real-world and clinical-study data sources.
The Scrip Awards also recognized PAREXEL and its collaboration with EMD Serono (a business of Merck KGaA, Darmstadt, Germany), MedCodeWorld and Intermountain Healthcare, with its inaugural award for “Best Use of Real-World Evidence.” The winning project aimed to overcome challenges faced when using real-world healthcare data to identify patients with specific subtypes of Multiple Sclerosis (MS), identify high disease activity (HDA), evaluate disability by ICD-based EDSS/KFSS, and characterize relapse events, via validated algorithms.
“These recognitions for PAREXEL’s Real-World Evidence capabilities are particularly significant in light of the recent FDA framework issued that highlights the growing importance of RWE to the industry,” said Michelle Hoiseth, Chief Data Officer of PAREXEL. “The framework indicates a commitment to expanding the regulatory model to include RWE approaches, and PAREXEL’s award-winning applications are strong examples of solutions to leverage RWE and help move healthcare forward.”
PAREXEL was also recognized by Scrip for “Best Technological Development in Clinical Trials – Clinical Sponsor-focused” for its Perceptive® Cloud, and “Best Contract Research Organization – Full Service Providers.”
Locally, PAREXEL was named one of the largest life science companies in Massachusetts by the Boston Business Journal. In addition, Health Advances, a PAREXEL company, was named to the Boston Globe’s “2018 Top Places to Work in Massachusetts,” in the medium-sized companies category.
“We are honored by these acknowledgements as they highlight different areas and aspects of our business, demonstrating PAREXEL’s commitment to innovation and the power of partnering to provide meaningful solutions and accelerate access to medicines for patients,” said Jamie Macdonald, CEO of PAREXEL.
About PAREXEL International
PAREXEL International Corporation is a leading innovator of global biopharmaceutical services. We simplify our clients’ journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services. PAREXEL develops breakthrough innovations and solutions by leveraging its comprehensive therapeutic, technical and functional expertise, in more than 100 countries around the world. For more information, visit our website and follow us on LinkedIn and Twitter.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
Source: PAREXEL International Corporation